Surfactant are alveolar surface reducing agents,used in preterm baby having lower pool surfactant i.e. respiratory distress syndrome. Sedation and pain reducing drug administration during surfactant therapy by less invasive technique will be assessed in this trial.
Not Applicable
- Conditions
- Health Condition 1: P220- Respiratory distress syndrome of newborn
- Registration Number
- CTRI/2022/03/041453
- Lead Sponsor
- IPGMER SSKM HOSPITA
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Preterm baby with gestational age between 28 to 34 weeks diagnosed with RDS will enroll in this study . RDS will be diagnosed clinically initially and later confirm by chest X ray .
A written informed consent will be obtained from the parents of the baby for participation in the study
Exclusion Criteria
Baby with major congenital anomaly .
Perinatal asphyxia (cord blood pH <7.2).
Intubated at delivery room.
Alternative cause of respiratory distress.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method